Aug 24, 2026 9:25 am EDT Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
Aug 13, 2026 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 10, 2026 8:30 am EDT Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
Jul 30, 2026 9:30 am EDT Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
Jul 29, 2026 10:05 am EDT The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
Jul 27, 2026 11:00 am EDT Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
Jun 26, 2026 10:02 am EDT Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Jun 26, 2026 9:05 am EDT Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference